Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Jin Peng He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9149-2247; OpenAlex author ID A5078198832, A5135361905, A5139426582. Sources: OpenAlex.

Their work

Papers
166 (first author 3, last author 30)
Trials
0
Grants
0
Labs led
1
Collaborators
514
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 10 papers · 2018: 15 papers · 2019: 14 papers · 2020: 15 papers · 2021: 18 papers · 2022: 29 papers · 2023: 18 papers · 2024: 12 papers · 2025: 19 papers · 2026: 10 papers

Papers 50 of 166

  1. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  2. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  3. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  4. Integrated driver gene-based survival prediction in resected pancreatic cancer. Last author DOI 10.1093/bjs/znag123↗
  5. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  6. Patient-derived Organoid Pharmacotyping as a Predictive Tool for Therapeutic Selection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006517↗
  7. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  8. KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity. Co-author DOI 10.1158/0008-5472.can-25-3126↗
  9. Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. Co-author DOI 10.1016/j.ijrobp.2022.07.1120↗
  10. [Reshaping surgical strategies for pancreatic cancer in the era of neoadjuvant therapy: challenges and opportunities]. Co-author DOI 10.3760/cma.j.cn112139-20260311-00097↗
  11. Palliative management for malignant biliary obstruction and gastric outlet obstruction from pancreatic cancer. Last author DOI 10.1002/ags3.12902↗
  12. Comparative spatial transcriptomics of pancreatic cancer with ductal and acinar origins in mouse models. Co-author DOI 10.1002/ctm2.70416↗
  13. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  14. Mild Dilatation of the Main Pancreatic Duct Is a Risk Factor for Progression to Pancreatic Cancer in High-Risk Individuals. Co-author DOI 10.1016/j.gastha.2025.100802↗
  15. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  16. Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis. Co-author DOI 10.1093/jnci/djae294↗
  17. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  18. Defining the Minimal and Optimal Thresholds for Lymph Node Resection and Examination for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: A M… Co-author DOI 10.1097/sla.0000000000006295↗
  19. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Last author DOI 10.1097/sla.0000000000006794↗
  20. The Organ-Specific Prognostic Value of TP53 Mutations in Pancreatic Cancer Patients with Oligometastasis Following Surgical Resection. Last author DOI 10.1097/sla.0000000000006823↗
  21. Transitional Subtype of Circulating Tumor Cells in Early Post-Operative Period of 5-Year Survivors Following Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006925↗
  22. Personalizing CA125 Levels Using Tumor Marker Variants: A Case-Control Analysis of Diagnostic Performance for Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-25-1050↗
  23. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  24. Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. Co-author DOI 10.1200/po-24-00494↗
  25. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z↗
  26. ASO Author Reflections: The Impact of Adjuvant Therapy in the Era of Neoadjuvant Strategies for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17788-7↗
  27. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  28. Editorial: To Beam, or Not to Beam-That Is the Question: Reflecting on the Role of Neoadjuvant Radiotherapy in Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18210-y↗
  29. Factors Associated With Aborted Whipple Procedures for Periampullary Carcinoma: A Multicenter Case-Control Study by the SAR Pancreatic Ductal Adenocarcinoma Di… Co-author DOI 10.2214/ajr.24.32160↗
  30. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  31. Factors associated with radiological misstaging of pancreatic ductal adenocarcinoma: A retrospective observational study. Co-author DOI 10.1067/j.cpradiol.2024.03.001↗
  32. Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002326↗
  33. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection. Co-author DOI 10.1097/sla.0000000000005977↗
  34. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Co-author DOI 10.1097/sla.0000000000006538↗
  35. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  36. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  37. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Co-author DOI 10.1200/jco.23.01573↗
  38. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  39. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193↗
  40. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-024-14942-5↗
  41. Feasibility of Early Diagnosis of Pancreatic Cancer using reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine Co-author DOI 10.21203/rs.3.rs-5011761/v1↗
  42. Seeking the Real Benefits of Laparoscopic Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1001/jamasurg.2023.5219↗
  43. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Co-author DOI 10.1002/jhbp.1303↗
  44. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  45. Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic. Co-author DOI 10.1007/s00520-023-07795-3↗
  46. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. Last author DOI 10.1007/s11605-022-05476-w↗
  47. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. Co-author DOI 10.1016/j.ejso.2023.04.009↗
  48. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  49. Tissue clearing and 3D reconstruction of digitized, serially sectioned slides provide novel insights into pancreatic cancer. Co-author DOI 10.1016/j.medj.2022.11.009↗
  50. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗

Closest collaborators

The 25 strongest of 514 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard Andrew Burkhart · 59 shared papers, 2018–2026 · strength 7.50
  2. Christopher Lee Wolfgang · 73 shared papers, 2013–2026 · strength 7.21
  3. Ammar A. Javed · 47 shared papers, 2016–2026 · strength 6.44
  4. Lei Zheng · 47 shared papers, 2013–2026 · strength 5.65
  5. Amol Kumar Narang · 37 shared papers, 2017–2026 · strength 4.77
  6. Joseph R. Habib · 27 shared papers, 2020–2026 · strength 4.60
  7. Kelly J. Lafaro · 29 shared papers, 2020–2026 · strength 4.56
  8. Matthew John Weiss · 49 shared papers, 2015–2024 · strength 4.19
  9. Ralph H. Hruban · 41 shared papers, 2013–2026 · strength 4.10
  10. Christopher L. Wolfgang · 26 shared papers, 2018–2025 · strength 3.59
  11. William R. Burns · 26 shared papers, 2020–2025 · strength 3.31
  12. Joseph M. Herman · 29 shared papers, 2013–2026 · strength 3.30
  13. Benedict Kinny‐Köster · 21 shared papers, 2020–2025 · strength 3.16
  14. Daniel A. Laheru · 28 shared papers, 2015–2025 · strength 3.04
  15. Michael Goggins · 25 shared papers, 2017–2026 · strength 3.02
  16. Jun Yu · 28 shared papers, 2017–2024 · strength 2.82
  17. Elliot K. Fishman · 25 shared papers, 2015–2024 · strength 2.59
  18. Vincent P. Groot · 24 shared papers, 2018–2026 · strength 2.59
  19. Izaak Quintus Molenaar · 16 shared papers, 2018–2026 · strength 2.46
  20. Colin Hill · 15 shared papers, 2021–2026 · strength 2.42
  21. Alex B. Blair · 24 shared papers, 2017–2022 · strength 2.37
  22. Ding Ding · 22 shared papers, 2018–2023 · strength 2.33
  23. Lois A. Daamen · 12 shared papers, 2023–2026 · strength 2.31
  24. Marc G. Besselink · 13 shared papers, 2019–2026 · strength 2.20
  25. Abhinav V. Reddy · 13 shared papers, 2021–2026 · strength 2.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.